The spend to get to cashflow positive is not all that speculative. You can look at some of the competition and get a sense that the spend will be at least $50M per year for the next 3 years. Then cash bleed will slow down assuming the product launch is successful and if there is not $100M in the bank at any given time then the offering will dilute.
What most of the investors have not comprehended is that management have been more focused on keeping their jobs than delivering shareholder value. The misalignment is common in the medtech worlds. Repricing the options signals management feel they have finally bottomed out so that is a positive sign but no one really knows if the market will be kind to the SP moving forward. That will take a heck of a lot of scooping from those so called weak hands or perhaps smart money depending on your perspective.
I see value here at some point but too early to jump in right now with fresh cash but you guys keep scooping and see how that works out for you if this thing goes south. More likely that is a pile of BS from the daytraders on this forum.
I will wait for a partnership deal that gives Titan a solid footing. It will come ... mark me.
News 
Market Data 
Discover 
